MORF - Morphic Holding Inc Stock Price, Fair Value and News

27.69USD-1.06 (-3.69%)Market Closed

Market Summary

USD27.69-1.06

Market Closed

-3.69%

MORF Stock Price

View Fullscreen

MORF RSI Chart

MORF Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-9.11

Price/Sales (Trailing)

2.7K

EV/EBITDA

-8.81

Price/Free Cashflow

-12.2

MORF Price/Sales (Trailing)

MORF Profitability

EBT Margin

-29119.96%

Return on Equity

-21.82%

Return on Assets

-21.05%

Free Cashflow Yield

-8.2%

MORF Fundamentals

MORF Revenue

Revenue (TTM)

521.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

MORF Earnings

Earnings (TTM)

-152.1M

Earnings Growth (Yr)

-67.1%

Earnings Growth (Qtr)

-12.49%

Breaking Down MORF Revenue

Last 7 days

-0.6%

Last 30 days

-13.9%

Last 90 days

-5.6%

Trailing 12 Months

-40.7%

How does MORF drawdown profile look like?

MORF Financial Health

Current Ratio

28.94

MORF Investor Care

Shares Dilution (1Y)

26.57%

Diluted EPS (TTM)

-3.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	53.2M	35.7M	18.1M	521.0K
2022	32.5M	45.3M	58.1M	70.8M
2021	42.6M	38.8M	16.1M	19.8M
2020	24.0M	31.0M	38.0M	44.9M
2019	9.1M	14.9M	20.7M	17.0M
2018	0	0	0	3.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Morphic Holding Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	rogers bruce	acquired	31,931	4.3151	7,400	president
Jan 16, 2024	rogers bruce	sold	-173,576	27.4907	-6,314	president
Jan 16, 2024	schegerin marc	sold	-166,071	27.4907	-6,041	cfo and coo
Jan 16, 2024	farrell robert e jr	sold	-139,900	27.4907	-5,089	svp finance and cao
Jan 16, 2024	tipirneni praveen p.	sold	-382,753	27.4907	-13,923	ceo
Jan 16, 2024	devaul william	sold	-123,956	27.4907	-4,509	general counsel and secretary
Jan 14, 2024	rogers bruce	acquired	-	-	5,070	president
Jan 14, 2024	tipirneni praveen p.	acquired	-	-	12,500	ceo
Jan 14, 2024	schegerin marc	acquired	-	-	4,690	cfo and coo
Jan 14, 2024	devaul william	acquired	-	-	3,250	general counsel and secretary

Which funds bought or sold MORF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.38	-103,000	44,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	6.93	144,711	560,619	-%
Apr 12, 2024	DNB Asset Management AS	new	-	231,898	231,898	-%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	51.00	282	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	58.00	58.00	-%
Apr 05, 2024	GAMMA Investing LLC	added	242	623	845	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	1,271	1,271	-%
Mar 11, 2024	VANGUARD GROUP INC	added	10.14	18,751,000	67,031,800	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	276	28,949,200	36,681,300	-%

Are Funds Buying or Selling MORF?

Are funds buying MORF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MORF

No. of Funds

Unveiling Morphic Holding Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ecor1 capital, llc	0.4%	211,262	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	9.2%	4,591,000	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	0.4%	211,262	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	polaris partners vii, l.p.	3.7%	1,860,498	SC 13G/A
Feb 09, 2024	artal international s.c.a.	4.3%	2,138,188	SC 13G/A
Feb 08, 2024	wellington management group llp	6.79%	3,377,310	SC 13G
Jan 26, 2024	blackrock inc.	6.6%	3,302,686	SC 13G/A
Jan 24, 2024	state street corp	5.15%	2,564,058	SC 13G
Oct 18, 2023	springer timothy a	15.8%	7,577,651	SC 13D

Recent SEC filings of Morphic Holding Inc

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	4	Insider Trading
Mar 19, 2024	3	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 12, 2024	8-K	Current Report
Feb 22, 2024	10-K	Annual Report
Feb 22, 2024	8-K	Current Report
Feb 22, 2024	S-8	Employee Benefits Plan
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Morphic Holding Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Morphic Holding Inc News

Latest updates

Morphic Holding Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	1,533,750	3,067,500	4,601,250	6,135,000	2,055,000	60,236,000	34,896,250	9,556,500	3,124,000	3,848,000	3,265,000	5,901,000	25,757,000	7,693,000	5,594,000	5,634,500	5,675,000	5,567,000	6,068,000	3,358,000
Costs and Expenses	10.5%	49,431,000	44,748,000	45,302,000	39,726,000	32,716,000	33,548,000	33,886,000	34,054,000	31,101,500	28,242,000	31,691,000	24,566,000	23,880,000	20,749,000	24,113,000	23,383,000	20,246,000	15,533,000	15,984,000	12,202,000	9,330,000
S&GA Expenses	-7.8%	9,579,000	10,384,000	9,583,000	9,277,000	8,014,000	8,303,000	8,234,000	7,591,000	7,443,500	7,276,000	7,139,000	5,953,000	5,126,500	4,751,000	4,195,000	4,423,000	3,426,000	2,898,000	2,077,000	1,832,000	-
R&D Expenses	16.0%	39,852,000	34,364,000	35,719,000	30,449,000	24,702,000	25,245,000	25,652,000	26,463,000	23,658,000	20,966,000	24,552,000	18,613,000	18,753,500	15,998,000	19,918,000	18,960,000	16,820,000	12,635,000	13,907,000	10,370,000	-
EBITDA Margin	-3792.1%	-289	-7.43	-3.60	-1.18	-0.82	-0.95	-1.10	-3.22	-4.77	-5.64	-1.57	-1.15	-	-	-	-	-	-	-	-	-
Income Taxes	53.0%	127,000	83,000	138,000	32,000	36,000	29,000	2,000	-	-	-	-	-	-143,000	-115,000	-155,000	-157,000	344,000	304,000	135,000	129,000	-
Earnings Before Taxes	-12.4%	-40,608,000	-36,129,000	-38,875,000	-36,103,000	-24,341,000	-29,992,000	26,843,000	-31,484,000	-21,402,000	-25,041,000	-27,815,000	-21,284,000	-17,892,000	5,239,000	-16,013,000	-16,903,000	-19,487,500	-8,560,000	-9,298,000	-5,071,000	-
EBT Margin	-3789.8%	-291	-7.49	-3.63	-1.19	-0.83	-0.97	-1.13	-3.25	-4.83	-5.70	-1.59	-1.17	-	-	-	-	-	-	-	-	-
Net Income	-12.5%	-40,735,000	-36,212,000	-39,013,000	-36,135,000	-24,377,000	-30,021,000	26,841,000	-31,484,000	-21,402,000	-25,041,000	-27,815,000	-21,284,000	-17,749,000	5,354,000	-15,858,000	-16,746,000	-19,831,000	-8,864,000	-9,433,000	-5,200,000	-5,343,000
Net Income Margin	-3791.2%	-291	-7.50	-3.63	-1.20	-0.83	-0.97	-1.13	-3.25	-4.83	-5.69	-1.59	-1.16	-	-	-	-	-	-	-	-	-
Free Cashflow	3.0%	-28,667,000	-29,555,000	-23,327,000	-32,004,000	-25,182,000	-25,143,000	-22,821,000	-28,196,000	-21,042,000	-24,936,000	-18,062,000	-20,441,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-2.8%	723	744	749	442	369	389	414	397	426	439	439	460	242	222	212	229	247	260	179	189
Current Assets	-2.9%	717	738	743	436	362	382	407	389	418	435	437	457	239	218	209	226	244	257	173	187
Cash Equivalents	-21.1%	59.00	74.00	217	42.00	59.00	85.00	141	120	171	184	399	396	102	98.00	133	107	102	160	44.00	186
Net PPE	21.4%	3.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00
Liabilities	24.8%	25.00	20.00	19.00	15.00	19.00	24.00	26.00	84.00	90.00	88.00	92.00	91.00	97.00	91.00	97.00	101	107	101	105	102
Current Liabilities	28.4%	25.00	19.00	18.00	13.00	17.00	19.00	20.00	44.00	38.00	42.00	35.00	34.00	39.00	36.00	45.00	37.00	35.00	26.00	44.00	35.00
Shareholder's Equity	-3.6%	697	723	729	427	349	365	388	313	337	350	348	369	145	130	115	128	141	159	-	-
Retained Earnings	-10.0%	-449	-408	-372	-333	-297	-272	-242	-269	-238	-216	-191	-163	-142	-124	-130	-114	-97.51	-77.68	-68.82	-54.18
Additional Paid-In Capital	0.9%	1,144	1,133	1,104	761	650	642	633	585	575	567	540	533	288	255	245	242	238	237	3.00	2.00
Shares Outstanding	0.0%	50.00	50.00	48.00	40.00	39.00	38.00	38.00	37.00	36.00	35.00	35.00	34.00	-	-	-	-	-	-	-	-
Float	-	-	-	2,140	-	-	-	559	-	-	-	1,018	-	-	-	318	-	-	-	374	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	2.3%	-28.57	-29.25	-23.03	-31.45	-25.12	-24.89	-22.82	-28.15	-20.58	-24.58	-17.91	-20.39	-14.42	4.00	-16.36	-18.94	-14.07	-13.70	-14.07	0.00	-
Share Based Compensation	-0.2%	11.00	11.00	10.00	10.00	7.00	8.00	8.00	7.00	6.00	6.00	5.00	4.00	3.00	3.00	2.00	3.00	1.00	1.00	1.00	0.00	-
Cashflow From Investing	109.7%	13.00	-133	-133	-88.40	-1.15	-32.51	3.00	-26.07	5.00	-211	20.00	74.00	-11.29	-46.05	42.00	24.00	-44.20	34.00	18.00	-143	-
Cashflow From Financing	-99.8%	0.00	19.00	332	102	1.00	1.00	41.00	3.00	3.00	22.00	1.00	241	30.00	7.00	1.00	1.00	0.00	95.00	-	-	-

MORF Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaboration revenue	$ 521	$ 70,808	$ 19,794
Operating expenses:
Research and development	140,384	102,062	87,789
General and administrative	38,823	32,142	27,811
Total operating expenses	179,207	134,204	115,600
Loss from operations	(178,686)	(63,396)	(95,806)
Other income:
Interest income, net	26,969	4,567	272
Other income (expense), net	2	(145)	(8)
Total other income, net	26,971	4,422	264
Loss before provision for income taxes	(151,715)	(58,974)	(95,542)
Provision for income taxes	(380)	(67)	0
Net loss	$ (152,095)	$ (59,041)	$ (95,542)
Net loss per share, basic (in dollars per share)	$ (3.59)	$ (1.55)	$ (2.67)
Net loss per share, diluted (in dollars per share)	$ (3.59)	$ (1.55)	$ (2.67)
Weighted average common shares outstanding, basic (in shares)	42,390,554	38,112,498	35,797,969
Weighted average common shares outstanding, diluted (in shares)	42,390,554	38,112,498	35,797,969
Comprehensive loss:
Net loss	$ (152,095)	$ (59,041)	$ (95,542)
Other comprehensive income (loss):
Unrealized holding losses on marketable securities, net of tax	5,627	(2,857)	(461)
Total other comprehensive income (loss)	5,627	(2,857)	(461)
Comprehensive loss	$ (146,468)	$ (61,898)	$ (96,003)

MORF Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 58,577	$ 59,272
Marketable securities	645,772	288,976
Accounts receivable	0	455
Prepaid expenses and other current assets	12,579	13,479
Total current assets	716,928	362,182
Operating lease right-of-use assets	2,133	3,514
Property and equipment, net	2,767	2,119
Restricted cash	560	560
Other assets	126	214
Total assets	722,514	368,589
Current liabilities:
Accounts payable	7,698	3,475
Accrued and other current expenses	17,078	13,181
Deferred revenue, current portion	0	470
Total current liabilities	24,776	17,126
Long-term liabilities:
Operating lease liability, net of current portion	716	2,344
Total liabilities	25,492	19,470
Commitments and contingencies (Note 11)
Stockholders’ Equity
Preferred shares, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common shares, $0.0001 par value, 400,000,000 shares authorized, 49,747,286 shares issued and outstanding as of December 31, 2023 and 38,584,678 shares issued and outstanding as of December 31, 2022	5	4
Additional paid‑in capital	1,143,919	649,549
Accumulated deficit	(449,190)	(297,095)
Accumulated other comprehensive income (loss)	2,288	(3,339)
Total stockholders’ equity	697,022	349,119
Total liabilities and stockholders’ equity	$ 722,514	$ 368,589

About Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ÃƒÅ¸7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ÃƒÅ¸7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avÃƒÅ¸8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with SchrÃƒÂ¶dinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CEO	Dr. Praveen P. Tipirneni M.D.
WEBSITE	morphictx.com
INDUSTRY	Biotechnology
EMPLOYEES	110

Morphic Holding Inc Frequently Asked Questions

What is the ticker symbol for Morphic Holding Inc? What does MORF stand for in stocks?

MORF is the stock ticker symbol of Morphic Holding Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Morphic Holding Inc (MORF)?

As of Wed Apr 24 2024, market cap of Morphic Holding Inc is 1.39 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MORF stock?

You can check MORF's fair value in chart for subscribers.

What is the fair value of MORF stock?

You can check MORF's fair value in chart for subscribers. The fair value of Morphic Holding Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Morphic Holding Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MORF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Morphic Holding Inc a good stock to buy?

The fair value guage provides a quick view whether MORF is over valued or under valued. Whether Morphic Holding Inc is cheap or expensive depends on the assumptions which impact Morphic Holding Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MORF.

What is Morphic Holding Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, MORF's PE ratio (Price to Earnings) is -9.11 and Price to Sales (PS) ratio is 2.66 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MORF PE ratio will change depending on the future growth rate expectations of investors.